Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.

Authors

Jean M Ruddy, Anne Kroman, Catalin F Baicu, Michael R Zile

Published in

Cardiac electrophysiology clinics. Volume 18. Issue 3. Pages 303-314.

Abstract

A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality of life, decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), and improving functional class. BAT was approved by the FDA for improvement of symptoms of heart failure for patients who remain symptomatic despite treatment with guideline-directed management, are New York Heart Association Class III or Class II (with a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, an NT-proBNP < 1600 pg/mL and excluding patients indicated for cardiac resynchronization therapy.

PMID:
42580795
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.